SOURCE: SomaLogic

SomaLogic

December 01, 2015 06:00 ET

SomaLogic Announces College of American Pathologists (CAP) Accreditation of Its CLIA Laboratory

Novel SOMAmer® Reagent-Based Tests to Be Offered From CMS-Registered Testing Facility

BOULDER, CO--(Marketwired - December 01, 2015) - SomaLogic, Inc. announced today that its SomaLogic Clinical Laboratory (CLIA laboratory) has been registered with the Centers for Medicare and Medicaid Services (CMS) under the Clinical Laboratory Improvement Amendments of 1988, and has received accreditation by the College of American Pathologists (CAP).

"The CAP accreditation of our CLIA laboratory is an important milestone on our way to applying our unique proteomic technology to the transformation of research and clinical diagnostics," said Byron Hewett, CEO of SomaLogic. "Through our CLIA laboratory, we will be able to provide a growing range of cutting-edge tests and assays across many different diseases for the academic and pharmaceutical research communities and, soon, for clinical providers and their patients."

SomaLogic's upcoming new SOMAmer reagent-based test offerings from its CLIA laboratory are based on novel protein biomarker combinations, or "signatures," which have been discovered through the application of the company's SOMAscan® assay to wide array of many different diseases and conditions.

SomaLogic's CMS Registration Number is 06D2093281, and its CAP Accreditation Number is 7223571. SomaLogic is in full compliance with all provisions (including the Privacy and Security Rules) of the Health Insurance Portability and Accountability Act of 1996.

For more information about the SomaLogic CLIA laboratory, please visit http://www.somalogic.com/Products-Services/CLIA-laboratory.aspx.

About SomaLogic
SomaLogic is transforming healthcare by applying our proprietary protein-measurement technology to the development of new diagnostic tests that deliver a higher quality of life by detecting diseases at their earliest stages and monitoring general wellness. Our ultimate goal is the "Wellness Chip," a single cost-effective and reliable blood test for multiple diseases and conditions that will enable healthcare providers to precisely monitor each individual's state of health and wellness in real time.

Our technology also has multiple potential applications in both life sciences and therapeutics, and it is now available to the entire biomedical scientific community for their own research needs. For more information, please visit http://www.somalogic.com.

Contact Information

  • Editorial Contact
    Fintan R. Steele, Ph.D.
    Executive Director of Corporate Communications
    fsteele@somalogic.com
    +1 720-214-3080 - T
    +1 617-816-9834 - M